JP2018522880A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522880A5
JP2018522880A5 JP2017568234A JP2017568234A JP2018522880A5 JP 2018522880 A5 JP2018522880 A5 JP 2018522880A5 JP 2017568234 A JP2017568234 A JP 2017568234A JP 2017568234 A JP2017568234 A JP 2017568234A JP 2018522880 A5 JP2018522880 A5 JP 2018522880A5
Authority
JP
Japan
Prior art keywords
cancer
dengue virus
denv
composition according
pfu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017568234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522880A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/040787 external-priority patent/WO2017004567A1/en
Publication of JP2018522880A publication Critical patent/JP2018522880A/ja
Publication of JP2018522880A5 publication Critical patent/JP2018522880A5/ja
Priority to JP2021113634A priority Critical patent/JP2021176862A/ja
Pending legal-status Critical Current

Links

JP2017568234A 2015-07-02 2016-07-01 デングウイルス及び樹状細胞による併用療法のための組成物及び方法 Pending JP2018522880A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021113634A JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562231351P 2015-07-02 2015-07-02
US62/231,351 2015-07-02
PCT/US2016/040787 WO2017004567A1 (en) 2015-07-02 2016-07-01 Compositions and methods for combination therapy with dengue virus and dendritic cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021113634A Division JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2018522880A JP2018522880A (ja) 2018-08-16
JP2018522880A5 true JP2018522880A5 (enExample) 2019-08-08

Family

ID=57609586

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017568234A Pending JP2018522880A (ja) 2015-07-02 2016-07-01 デングウイルス及び樹状細胞による併用療法のための組成物及び方法
JP2021113634A Pending JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021113634A Pending JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Country Status (8)

Country Link
US (6) US9730989B2 (enExample)
EP (1) EP3316897A4 (enExample)
JP (2) JP2018522880A (enExample)
CN (1) CN107921063A (enExample)
CA (1) CA2991212A1 (enExample)
DE (1) DE202016008300U1 (enExample)
MX (1) MX2018000052A (enExample)
WO (1) WO2017004567A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9730989B2 (en) 2015-07-02 2017-08-15 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
CA2999881A1 (en) * 2015-09-26 2017-03-30 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
US12274725B2 (en) 2017-06-12 2025-04-15 Washington University Zika virus strains for treatment of glioma
SG11201912163WA (en) * 2017-06-15 2020-01-30 Primevax Immuno Oncology Inc Compositions and methods for cancer therapy with dengue virus and dendritic cells

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1015972A (en) 1905-09-25 1912-01-30 Westinghouse Electric & Mfg Co Electric switch.
US1035755A (en) 1908-07-21 1912-08-13 Glenn S Smith Draftsman's apparatus.
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AU2872199A (en) * 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
US6524587B1 (en) 1998-05-05 2003-02-25 Bruce W. Lyday Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors
US6048686A (en) 1998-05-05 2000-04-11 Randy Kyle Brown Hyperthermia and immunotherapy for cancer
WO2000057909A2 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
EP1165127B1 (en) 1999-03-26 2008-12-31 Walter Reed Army Institute of Research Multivalent dengue virus vaccine
EP1168924A4 (en) * 1999-03-31 2002-09-04 Univ Pittsburgh DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL
EP1484064A1 (en) 2003-06-04 2004-12-08 Gesellschaft für Biotechnologische Forschung Therapeutical composition containing dentritic cells and use thereof
WO2006001120A1 (ja) 2004-06-24 2006-01-05 Dnavec Research Inc. マイナス鎖rnaウイルスを含む抗癌剤
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
JP5020935B2 (ja) * 2005-04-08 2012-09-05 アルゴス セラピューティクス，インコーポレイティド 樹状細胞組成物および方法
PL2589602T3 (pl) 2006-08-15 2016-11-30 Rozwinięcie komponentów szczepionki przeciwko wirusowi dengi
CA2700436C (en) * 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
RU2575978C2 (ru) 2010-03-15 2016-02-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Система и способ получения и хранения активированных зрелых дендритных клеток
EP2714076A1 (en) 2011-05-26 2014-04-09 GlaxoSmithKline Biologicals S.A. Inactivated dengue virus vaccine
EP2543386A1 (en) * 2011-07-05 2013-01-09 Sotio a.s. Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure
US9879003B2 (en) 2012-04-11 2018-01-30 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
JP2015520196A (ja) * 2012-06-10 2015-07-16 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. デングウイルスに対するワクチン投与のための組成物および方法
ES2738582T3 (es) 2014-02-14 2020-01-23 Immune Design Corp Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica
KR102873947B1 (ko) 2015-05-07 2025-10-22 베이롤 칼리지 오브 메드신 수지상 세포 면역요법
US9730989B2 (en) 2015-07-02 2017-08-15 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
CA2999881A1 (en) 2015-09-26 2017-03-30 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
SG11201912163WA (en) 2017-06-15 2020-01-30 Primevax Immuno Oncology Inc Compositions and methods for cancer therapy with dengue virus and dendritic cells

Similar Documents

Publication Publication Date Title
JP2018522880A5 (enExample)
JP2016531927A5 (enExample)
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
WO2015193359A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
MX2016014711A (es) Inmunoterapia novedosa contra varios tumores de la sangre, con la leucemia mielogena aguda (lma).
JP2013177430A5 (enExample)
WO2015013461A3 (en) Cancer vaccination with antigen evolution
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
GB0700058D0 (en) Anti-tumor vaccine based on normal cells
MX2014009628A (es) Uniones a cdim y sus usos.
NZ711946A (en) Newcastle disease viruses and uses thereof
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
MX379423B (es) Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
MX376066B (es) Anticuerpos dirigidos contra cd127.
BR112013031084A2 (pt) meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
WO2018083220A3 (en) Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
RU2014117707A (ru) Способ лечения пролиферативного заболевания
CN104245736A (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
MX2021003826A (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
MX385304B (es) Nuevos complejos metálicos de nocardamina y su uso en composiciones farmacéuticas.